ArticleMethods in molecular biology (Clifton, N.J.)2026
Assay for Neurocan-Degrading Activity of ADAMTS-12 Metalloprotease.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) family members, including ADAMTS-12, play a significant role in the breakdown of proteoglycans such as versican and neurocan. ADAMTS-12 -mediated degradation of neurocan could be relevant to neuronal plasticity, inflammatory responses, and neural tissue repair. Investigating this process may provide novel insights into the molecular mechanisms underlying neurodegenerative diseases, therefore contributing to the development of potential therapeutic strategies. The method for evaluating the neurocanase activity of ADAMTS-12 may offer a valuable tool for studying extracellular matrix remodeling in the central nervous system. The findings may contribute to the development of targeted therapies aimed at modulating the extracellular matrix integrity in neurological disorders and broaden our understanding of protease-substrate interactions in both physiological and pathological conditions.
Indexed as
Identifiers
41917355What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.